

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

|                      |                   |
|----------------------|-------------------|
| Application Number   | 10/519,162        |
| Filing Date          | December 23, 2004 |
| First Named Inventor | Kazuo UMEZAWA     |
| Art Unit             | Not Yet Assigned  |
| Examiner Name        | Not Yet Assigned  |



Attorney Docket Number

09707.0001

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

| Examiner Initials | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Issue or<br>Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or Relevant<br>Figures Appear |
|-------------------|-----------------------|---|--|--|---|
|                   |                       | 4,861,872   | 08-29-1989                                 | Okamoto et al.                                     |   |
|                   |                       | 4,912,205   | 03-27-1990                                 | Okamoto et al.                                     |   |
|                   |                       |   |  |  |   |
|                   |                       |   |  |  |   |
|                   |                       |   |  |  |   |
|                   |                       |   |  |  |   |
|                   |                       |   |  |  |   |

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

## FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or Relevant<br>Figures Appear | Translation <sup>6</sup> |
|-------------------|-----------------------|--|--------------------------------|--|---|--------------------------|
|                   |                       | WO 00/02548  | 01-20-2000                     | Osteoscreen  |   |                          |
|                   |                       | JP63-178101  | 07-22-1988                     | Daicel Chem Ind. Ltd.                              |   | abstract                 |
|                   |                       | JP6-211902   | 08-02-1994                     | Daicel Chem Ind. Ltd.                              |   | yes                      |
|                   |                       | JP2001-296288  | 10-26-2001                     | Daicel Chem Ind. Ltd.                              |   | yes                      |
|                   |                       | JP2001-352986  | 12-25-2001                     | Kyowa Hakko Kogyo Co.<br>Ltd                       |   | yes                      |
|                   |                       | JP2002-128690  | 05-09-2002                     | Hirohata Tashinari                                 |   | yes                      |
|                   |                       |  |                                |  |   |                          |
|                   |                       |  |                                |  |   |                          |
|                   |                       |  |                                |  |   |                          |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item<br>(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),<br>publisher, city and/or country where published. | Translation <sup>6</sup> |
|-------------------|-----------------------|---|--------------------------|
|                   |                       | KOBAYASHI M., "Expression Regulation of TNF $\alpha$ in Adipocytes and Significance of Insulin Resistance", Igaku no ayumi, 184(6), pp. 562-66, (1998).   | yes                      |
|                   |                       | SCHEDDEL et al., "Synthesis of (R)-4,4-trifluoro-2-mercaptopbutyric acid", Tetrahedron: Asymmetry, 11, pp. 2125-317, (2000).  |                          |
|                   |                       | KURU et al., "TNF Expression in Muscular Disorder", Neuroimmunology 10, pp. 174-75 (2002).  | yes                      |
|                   |                       | NAKAMURA et al., "Inhibitory Effect of New NF- $\kappa$ B Inhibitor DHMEQ2 for Human Breast Cancer Cells", Proceedings of the Japanese Cancer Association, 61 <sup>st</sup> Annual Meeting, Abstract 3550, p. 157 (2002).   | yes                      |
|                   |                       | HORIGUCHI et al., "Antitumor Effect of a Novel Nuclear Factor- $\kappa$ B Activation Inhibitor in Bladder cancer Cells", Expert Rev. Anticancer Ther. 3, pp. 793-8 (2003).  |                          |
|                   |                       | CHAICHAROENPONG et al., "Preparation of Radioactively Labeled Dehydroxymethylepoxyquinomicin, an NF- $\kappa$ B Function Inhibitor", Drugs Exptl. Clin. Res. XXX, pp. 1-3 (2003).   |                          |
|                   |                       | MIYAJIMA et al., "New Nuclear Factor- $\kappa$ B Activation Inhibitor Prevents Inflammatory Injury in Unilateral Ureteral Obstruction", J. Urology 169, pp. 1559-63 (2003).   |                          |
|                   |                       | LIN et al., "(-)-Epigallocatechin-3-gallate Blocks the Induction of Nitric Oxide Synthase by Down-Regulating Lipopolysaccharide-Induced Activity of Transcription Factor Nuclear Factor- $\kappa$ B", Molecular Pharmacology 52, pp. 465-72 (1997).                   |                          |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.P./

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/519,162        |
| Filing Date            | December 23, 2004 |
| First Named Inventor   | Kazuo UMEZAWA     |
| Art Unit               | Not Yet Assigned  |
| Examiner Name          | Not Yet Assigned  |
| Attorney Docket Number | 09707.0001        |



## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials <sup>1</sup> | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.                              | Translation <sup>6</sup> |
|--------------------------------|-----------------------|---|--------------------------|
|                                |                       | OHLLSSON et al., "Oxidized Low Density Lipoprotein Inhibits Lipopolysaccharide-induced Binding of Nuclear Factor- $\kappa$ B to DNA and the Subsequent Expression of Tumor Necrosis Factor- $\alpha$ and Interleukin-1 $\beta$ in Macrophages", <i>J. Clin. Invest.</i> 98, pp. 78-89 (1996). |                          |
|                                |                       | ELIGINI et al., "Oxidized Phospholipids Inhibit Cyclooxygenase-2 in Human Macrophages Via Nuclear Factor- $\kappa$ B/IKB and ERK-2-dependent Mechanisms", <i>Cardiovascular Res.</i> 55, pp. 405-15 (2002).   |                          |
|                                |                       | ARIGA et al., Seikagaku, Journal of Japanese Biochemical Society, 73(8) Abstract (2001).  | yes                      |
|                                |                       | UMEZAWA K., "New Molecular Targets of Antidiabetic Agents and Anticancer Agents and Inhibitors", The 2 <sup>nd</sup> Annual Report of the Center for the Development of Molecular Target Drugs, Symposium on Molecular Target Drugs in Kanazawa, Abstract (2002).                             | yes                      |
|                                |                       | UMEZAWA K., "Role of Signal Transduction Inhibitors of Low Molecular Weight in Regenerative and Genetic Medicine", The 7 <sup>th</sup> Annual Scientific Meeting of Conference of Gene Therapy and Molecular Medicine, Abstract (2003).   | yes                      |
|                                |                       | ARIGA et al., "Synthesis of Novel Epoxydine Compound DHM2EQ and Its Suppression of NF- $\kappa$ B Action", The 4 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2000).  | yes                      |
|                                |                       | SHIMA et al., "Inhibition of NF- $\kappa$ B Inhibitor DHMEOQ of Adhesion Molecule Expression in vascular Cells", The 6 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2002).  | yes                      |
|                                |                       | WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using Novel NF- $\kappa$ B Inhibitor", The 6 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2002).   | yes                      |
|                                |                       | TAKAHASHI et al., "NF- $\kappa$ B Inhibition in Prostate Cancer Cells and Anti-Cancer Activity by DHMEOQ", The 7 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2003).  | yes                      |
|                                |                       | WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using Novel NF- $\kappa$ B Inhibitor", The 7 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract S3-4 (2003).  | yes                      |
|                                |                       | TATETSU et al., "In Vivo and in Vitro Studies of Novel NF- $\kappa$ B Inhibitor (DHMEOQ) in Myeloma Cells", The 28 <sup>th</sup> Annual Meeting of Japan Myeloma Study Group, Abstract (2003).  | yes                      |
|                                |                       | ARIGA et al., "Inhibition of NF- $\kappa$ B by a Novel Epoxydine Compound", The 59 <sup>th</sup> Annual Meeting, Abstract (2000).   | yes                      |
|                                |                       | KIKUCHI et al., "Apoptosis-Induction in Hormone-Refractory Prostate Cancer Using a Novel NF- $\kappa$ B Activation Inhibitor", Proceedings of the Japanese Cancer Association, The 60 <sup>th</sup> Annual Meeting, Abstract (2001).  | yes                      |
|                                |                       | SHIMA et al., "Inhibition of Adhesion Molecule Expression by a NF- $\kappa$ B Inhibitor DHMEOQ in Vascular Endothelial Cells", Proceedings of the Japanese Cancer Association, The 61 <sup>th</sup> Annual Meeting, Abstract (2002).  | yes                      |
|                                |                       | NAMIKAWA et al., "Inhibition of NF- $\kappa$ B Activity in Bladder Carcinoma Cells", Proceedings of the Japanese Cancer Association, The 61 <sup>th</sup> Annual Meeting, Abstract (2002).  | yes                      |
|                                |                       | WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using a Novel NF- $\kappa$ B Inhibitor", Proceedings of the Japanese Cancer Association, The 61 <sup>th</sup> Annual Meeting, Abstract, p 162 (3466), (2002).  | yes                      |
|                                |                       | MATSUMOTO et al., "NF- $\kappa$ B Inhibitor Enhances the Anti-Cancer Effect of TNF- $\alpha$ Treatment and Ionizing Radiation in P-53 Wild Pancreatic Cancer", Proceedings of the Japanese Cancer Association, The 62 <sup>nd</sup> Annual Meeting, Abstract, p. 160 (203-0A), (2003).        | yes                      |
|                                |                       | HORIE et al., Basic Studies of the Molecular Target Therapy of ATL Using a Novel NF- $\kappa$ B Inhibitor", Proceedings of the Japanese Cancer Association, The 62 <sup>nd</sup> Annual Meeting, Abstract, p. 153 (2039-0A), (2003).  | yes                      |
|                                |                       | SUZUKI et al., "Inhibition of Macrophage Activation by the Novel NF- $\kappa$ B Inhibitor, Dehydroxymethylpepoxyquinomicin", The 3 <sup>rd</sup> International Symposium on Natural Drugs, Naples, Abstract (2003).   |                          |
|                                |                       | ARIGA et al., "Molecular Design and Biological Activities of a New NF- $\kappa$ B Inhibitor, Dehydroxymethylpepoxyquinomicin (DHMEOQ)", Faculty of Science and Technology, Biology and Pathology, Keio University, Yokohama 223-0061, Japan, Abstract (2002).                                 |                          |
|                                |                       | UMEZAWA, "Molecular Design and Biological Activities of NF- $\kappa$ B and Protein-Tyrosine Phosphatase Inhibitors", Department of Applied Chemistry, Keio University, Ewha Woman's University Annual Symposium (Gosari) (2002).  |                          |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.P./

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet


3

of

3

## Complete if Known

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/519,162        |
| Filing Date            | December 23, 2004 |
| First Named Inventor   | Kazuo UMEZAWA     |
| Art Unit               | Not Yet Assigned  |
| Examiner Name          | Not Yet Assigned  |
| Attorney Docket Number | 09707.0001        |



## NON PATENT LITERATURE DOCUMENTS

|  |  |
|--|--|
|  | HORIGUCHI et al., "A Novel NF- $\kappa$ B Activation Inhibitor Mediated Apoptosis as a New Therapeutic Approach in Hormone-Refractory Prostate Cancer", American Urological Association Annual Meeting, Abstract (2002).   |
|  | MIYAJIMA et al., "Nuclear Factor- $\kappa$ B Activation Inhibitor Prevents Renal Tissue Damage in Unilateral Ureteral Obstruction", American Urological Association Annual Meeting, Abstract (2002).   |
|  | HORIGUCHI et al., "Anti-Tumor Effect of a Novel NF- $\kappa$ B Activation Inhibitor in Bladder Cancer Cells", American Urological Association Annual Meeting, Abstract (2003).   |
|  | UMEZAWA, "Molecular Design and Biological Activities of a New NF- $\kappa$ B Inhibitor, Dehydroxymethylepoxyquinomicin", The 5 <sup>th</sup> International Symposium on Molecular Medicine, Crete, Greece, Abstract (2002).  |
|  | NAMEKAWA et al., "Suppression of Human Breast Carcinomas in Mice by a Novel NF- $\kappa$ B Inhibitor DHMEQ", The 76 <sup>th</sup> Annual Meeting of the Japanese Biochemical Society, Abstract .   |
|  | SUZUKI et al., "Inhibition of Ligand-Induced Macrophage Activation by an NF- $\kappa$ B Inhibitors, DHMEQ", The 76 <sup>th</sup> Annual Meeting of the Japanese Biochemical Society, Abstract .  |
|  | KUBOTAL et al., "Application of an NF- $\kappa$ B Inhibitor to the Therapy of SLE", The 67 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology, Abstract (2003).   |
|  | HORIGUCHI et al., "Suppression of Hormone-Refractory Prostate Cancer by a Novel NF- $\kappa$ B Inhibitor in Nude Mice", Proceedings of the American Association for Cancer Research 93 <sup>rd</sup> Annual Meeting, Abstract 2163.  |
|  | ARIGA et al., "Inhibition of TNF-Alpha-Induced NF- $\kappa$ B Functions by a Synthetic Epoxyquinomicin Analogue", Proceedings of the American Association for Cancer Research 92 <sup>nd</sup> Annual Meeting, Abstract 2111.  |
|  | KIKUCHI et al., "A Novel Nf- $\kappa$ B Activation Inhibitor-Mediated Apoptosis As a New Therapeutic Approach In Hormone-Refractory Prostate Cancer", The 47 <sup>th</sup> Annual Congress of the Japan Section of the International College of Surgeons, Abstract (2001). |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Kyle Purdy/ | Date Considered | 08/22/2008 |
|--------------------|--------------|-----------------|------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.